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Background and objectives: Assessing health-related quality of life is an important aspect of
clinical practice. Thus, the present study attempts to assess the health-related quality of
life  of patients with chronic liver disease.
Methods: A cross-sectional survey was conducted on 133 chronic liver disease patients, using
three instruments: a demographic questionnaire, the Chronic Liver Disease Questionnaire,
and  Model for End-Stage Liver Disease index. Variables were expressed as frequencies,
percentages, means, and standard deviations. The statistical analysis included Pearson’s
correlation, Student’s t-test, and analysis of variance (p < 0.05 was considered signiﬁcant).
Results: The mean age of included subjects was 50.5 ± 13.3 years. The majority were male
(66.2%), Caucasian (70.7%), and had a family income of US$329–US$658.2. Over half of
the  patients (56.4%) were infected by hepatitis C virus and 93.2% had low Model for End-
Stage Liver Disease scores. Model for End-Stage Liver Disease score was related to age
(r  = 0.185; p = 0.033). Higher mean Chronic Liver Disease Questionnaire scores were obtained
for  emotional function (39.70/SD ± 12.98) and while lower scores were obtained for abdomi-
nal  symptoms (16.00/SD ± 6.25). Fifty-two patients (39.1%) presented overall low (<5) Chronic
Liver Disease Questionnaire scores. Furthermore, Chronic Liver Disease Questionnaire score
was related to family income (r = 0.187, p = 0.031).Conclusion: Most individuals presented high mean Chronic Liver Disease Questionnaire
scores, indicating low health-related quality of life, especially individuals with low family
substantially contributes to mortality and morbidity rates.income.
IntroductionChronic diseases in general are increasingly widespread,1
and diseases of the liver in particular are considered a
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global public health problem.2 Chronic liver disease (CLD)
3,4y, Arac¸atuba Dental School, Estadual Paulista University – UNESP,
ba, São Paulo, Brazil.
Worldwide, about 500 million individuals have CLD with
a viral etiology.5 However, CLD also has non-viral etiol-
ogy including alcoholic hepatitis, fatty liver, autoimmune
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epatitis, cryptogenic hepatitis, and other unidentiﬁed
auses.
Over the last few decades, assessing quality of life (QoL)
f individuals with diseases has become common clinical
ractice,6,7 as a consequence of increased survival of patients
ith chronic diseases.8 The term health-related quality of
ife (HRQoL) reﬂects the impact of the disease upon a per-
on’s quality of life. It is a subjective, multidimensional
oncept addressing various aspects of the individuals’ life
uch as age, gender, socioeconomic status, and type of illness,
nd treatment,9 that should be considered during patient
valuation.10
CLD has a negative impact on HRQoL since patients
ften present asthenia, indisposition, abdominal, muscle,
nd/or joint pain or discomfort, lack of appetite, insomnia,
nd complications related to liver cirrhosis, such as ascites,
ariceal bleeding in the stomach and esophagus, and hepatic
ncephalopathy. Moreover, CLD is linked to job loss, impaired
unctioning, mood swings, anxiety, low self-esteem, depres-
ion, and other emotional problems that severely affect QoL
nd well-being.11–15
Globally, studies on HRQoL of patients with CLD have used
eneric and speciﬁc instruments.16,17 Recently, a Japanese ver-
ion of the Chronic Liver Disease Questionnaire (CLDQ) to
ssess HRQoL was validated in patients with chronic viral
epatitis.18 To the best of our knowledge, this is the ﬁrst study
hat assesses the HRQoL of Brazilian patients with CLD using
 speciﬁc instrument that has been recently translated and
alidated for this population.19
ethods
atients
atients with CLD referred to the Outpatient Clinic of CLD
t Hospital das Clinicas of the Federal University of Uberlân-
ia, Minas Gerais State, Brazil in the period of 2011–2012 were
ecruited for the study. Patients of either gender had be 18
ears or more  and have a diagnosis of CLD by a hepatologist.
The diagnosis of chronic hepatitis B virus (HBV) infection
as based on the presence of hepatitis B surface antigen for
ore  than six months and elevated serum alanine amino-
ransferase levels with or without HBV DNA, detected by
eal-time polymerase chain reactions (PCR).20
Chronic hepatitis C virus (HCV) infection was diagnosed
ased on the presence of hepatitis C antibodies for more  than
ix months assessed by ELISA III and HCV RNA by qualita-
ive polymerase chain reaction and elevated serum alanine
minotransferase levels.21
Primary biliary cirrhosis was diagnosed based on posi-
ive anti-mitochondrial antibodies (AMA) and elevated liver
nzymes with or without liver biopsy.22 Alcohol was deemed
he cause of chronic liver disease if daily alcohol con-
umption was greater than 40 g for at least 10 years with
levated -glutamyl transferase when controlling for other
23iver diseases.
Autoimmune hepatitis diagnosis was based on simpliﬁed
iagnostic criteria for routine clinical practice including age,
ex, autoantibodies [smooth muscle actin (SMA), anti-nuclear5;1 9(6):590–595 591
antibody (ANA), AMA, liver-kidney microsomal antibod-
ies (LKM), soluble liver/liver-pancreas antibodies (SLA/LP)],
-globulins, immunoglobulin A, immunoglobulin G (IgG),
immunoglobulin M (IgM), absence of viral hepatitis, and liver
histology.24
Diagnosis of nonalcoholic fatty liver disease (NAFLD) was
based in the evidence of hepatic steatosis, either by imag-
ing or histology, controlling for other causes of secondary
hepatic fat accumulation such as signiﬁcant alcohol con-
sumption, steatogenic medication, or hereditary disorders.25
Cryptogenic chronic hepatitis was diagnosed if the patient
presented with persistent inﬂammation of the liver, unex-
plained by conventional clinical, laboratory, and histological
methods.26
Liver cirrhosis diagnosis was based on clinical, bio-
chemical, serologic, and radiographic parameters and
ultrasonography.27 Cirrhosis without a diagnosis of the eti-
ology was termed “other forms of cirrhosis or unspeciﬁed
cirrhosis”.
Exclusion criteria were presence of malignancy, liver trans-
plantation, co-infection with human immunodeﬁciency virus
(HIV), psychiatric or emotional problems, cognitive or lan-
guage difﬁculties that prevented the reliable application of the
questionnaire, and a diagnosis of hepatic encephalopathy.6
The study was conducted in accordance with the Helsinki Dec-
laration and study protocols were approved by local ethics
committees. All patients provided informed consent before
enrollment.
A pilot study to verify the applicability of these instruments
was ﬁrst conducted on 23 individuals with the same popula-
tion characteristics. These patients were not included in the
ﬁnal sample.
Data  collection
The investigators informed patients about the study aims.
After obtaining informed consent, participants completed a
socio-demographic questionnaire and the CLDQ.
The CLDQ has recently been translated and validated for
the Brazilian population.18 This instrument was developed
by Yonossi et al. in 1999 to assess QoL of patients with liver
diseases.6 The CLDQ is the only validated instrument for the
different etiologies and degrees of severity of liver disease.
It yields both domains and total scores, demonstrating both
multidimensional and overall perception of QoL, emphasizing
the effects of liver disease symptoms. The Brazilian version
comprises 29 questions encompassing six domains: Abdom-
inal Symptoms (AS), Fatigue (FA), Systemic Symptoms (SS),
Activity (AT), Emotional Function (EM), and Worry (WR). AS
and AT domains have 3 items each; FA, SS, and WR  have 5
items each; whereas EM comprises 8 items. Each item is rated
on a 7-point Likert scale.28 Higher score on the questionnaire
is indicative of minimum symptoms and lower score indi-
cates more  pronounced symptoms. A CLDQ cut-off score was
determined to evaluate HRQoL based on prior literature; mean
CLDQ scores ≥5 was considered to represent high HRQoL and
29mean CLDQ scores <5 implied low HRQoL.
The Model for End-Stage Liver Disease (MELD) index—a
mathematical model that uses three laboratory tests (values
of serum creatinine, serum total bilirubin, and international
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Table 1 – Socio-demographic characteristics of 133
chronic liver disease patients included in the study.
Variables n %
Gender
Female 45 33.8
Male 88 66.2
Race/ethnicity
No Caucasian 39 29.3
Caucasian 94 70.7
Age (years)
≤40 29  21.8
41–50 33 24.8
51–60 40 30.1
>60 31 23.3
Occupation
Retired 37 27.8
Unemployed 20 15.0
Housewife 10 7.5
Employee 57 42.9
Medical license 5 3.8
Prisoner 4 3.0
Family income (dollars)
<US$329 11 8.3
US$329 to US$658.2 58 43.6
US$658.2 to US$987.3 42 31.6
>US$987.3 21 15.8
Did not answer 1 0.8
Education level
Primary (4 years) 37 27.8
Secondary (5 and 8 years) 36 27.1
Incomplete high school (9 and 10 years) 21 15.8
High school (11 years) 28 21.1
Incomplete higher education (12 and 14 8 6.0592  b r a z j i n f e c t d 
normalized ratio; INR) to determine the severity of liver
disease30—was also calculated. The formula adopted by the
United States (U.S.) Department of Health & Human Ser-
vices was used: {0.957 × loge [creatinin (mg/dL)] + 0.378 × loge
[bilirubin (mg/dL)] + 1.120 × loge (INR) + 0.643} * 10.
For patients on dialysis more  than twice a week, cre-
atinine values were always registered at 4.0. All patients
were categorized into groups, based on MELD scores: low
(<15), moderate (16–25) and high (>25) risk of mortality.
The MELD is used as a tool to guide liver organ alloca-
tion system for liver transplantation in the US, Europe, and
Brazil.30
Statistical  analysis
Data were entered into Microsoft Excel, a spreadsheet
program. Frequencies of variables were crosschecked for accu-
racy. Subsequently, this database was transferred to Epi InfoTM
7.1.0.6, through which statistical analyses were performed.
Categorical variables (e.g., gender, race/ethnicity, etiology of
liver disease) are presented as frequencies and percentages,
whereas continuous variables (MELD and CLDQ scores) are
presented as means and standard deviations. To evaluate gen-
der differences in average CLDQ scores, a Student’s t-test was
used, while analysis of variance (ANOVA) was used to compare
differences in average CLDQ scores for different categories,
level of education, occupation, and family income (p < 0.05 was
considered signiﬁcant). Pearson’s correlation coefﬁcient was
used to verify the existence of correlation between the follow-
ing variables: CLDQ scores, MELD scores, age, education, and
family income.
Results
Sociodemographic  and  clinical  characteristics
The socio-demographic characteristics of 133 patients with
chronic liver disease of different etiologies are shown in
Table 1. The majority of participants in this study were male
(66.2%), Caucasian (70.7%), employed (42.9%), and had a fam-
ily income of US$329–US$658.2 (43.6%). Over 27% had received
up to four years of schooling. The participants’ mean age was
50 ± 13.3 years. Regarding chronic liver etiology, 75 individuals
were classiﬁed as chronic HCV patients (56.4%), 25 as HBV
patients (18.8%), 15 with alcoholic liver cirrhosis (11.3%), 8 with
autoimmune hepatitis (6%), 4 with NAFLD (3%), 1 with cryp-
togenic hepatitis (0.8%), and 5 had other causes of cirrhosis
(3.8%).
CLDQ
Table 2 shows the minimum, maximum, mean, and standard
deviation CLDQ scores. Higher mean CLDQ scores were found
for emotional function (39.70 ± 12.98) while lower mean CLDQ
scores were obtained for abdominal symptoms (16.00 ± 6.25).
Fifty-two patients (39.1%) obtained low (<5) overall CLDQ
scores. CLDQ was evaluated according to age, gender, fam-
ily income and school level. Family income was correlated to
CLDQ (r = 0.187, p = 0.031) (Table 3).years)
Completed higher education (15 years) 3 2.3
MELD
Regarding MELD, 124 (93.2%) individuals were at low risk (≤15),
seven (5.3%) were at moderate risk, and two (1.5%) were at high
risk for mortality (>25). MELD indices were correlated to age
(r = 0.185; p = 0.033; Table 3).
Discussion
Liver disease is a serious public health problem that affects
patients’ QoL. HRQoL measures are increasingly recognized
as important tools for assessing disease outcomes and deter-
mining health interventions.17 The present study showed high
mean CLDQ scores, indicating low HRQoL in the population
studied.
The majority of participants were male, Caucasian, and
infected by either hepatitis B or C viruses. This is consistent
with other studies using similar methods.31,32 We  selected the
CLDQ in order to measure the HRQoL of patients with liver
disease, regardless of etiology and severity.
Mean emotional functional CLDQ scores were high. The
awareness of potentially life-threatening diseases may have
adverse emotional effects on participants, regardless of bio-
logical consequences of the disease, as suggested by a prior
b r a z j i n f e c t d i s . 2 0 1 5;1 9(6):590–595 593
Table 2 – Chronic Liver Disease Questionnaire (CLDQ) score in domains.
Variable Minimum score Maximum score Mean score SD score
CLDQ domains
Abdominal symptoms 3 36 16.00 6.25
Fatigue 5 35 23.35 9.32
Systemic symptoms 7 35 27.29 6.76
Activity 3 21 16.45 5.19
Emotion function 10 56 39.70 12.98
Worry 5 35 25.69 9.99
Total CLDQ 8.16 33.83 24.75 6.68
Table 3 – Univariate regression analysis of potential predictors of Chronic Liver Disease Questionnaire (CLQD) and Model
End-Stage Liver Disease (MELD) scores, Brazil, 2012.
Variables Chronic Liver Disease Questionnaire (CLDQ) Model End-Stage Liver Disease (MELD)
Pearson correlation
coefﬁcient (r)
p-Value Pearson correlation
coefﬁcient (r)
p-Value
Meld −0.051 0.562 NA NA
Age −0.031 0.727 0.185 0.033*
Education level −0.061 0.486 −0.083 0.342
Family income 0.187 0.031* −0.096 0.271
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∗ p < 0.05.
tudy.10 Previous research has also shown that depressive dis-
rders are related to poor HRQoL in patients with CLD.13
The present study found a positive correlation between
LDQ scores and family income, implying that those with high
amily incomes had higher HRQoL, as demonstrated by Hsu
t al. (2012).33
On the other hand, CLDQ values were not related to age,
ender, and level of education. Previous studies have shown
hat gender and education level were not related to the HRQoL
f patients with liver disease.31,34,35 However, CLDQ scores
ecreased with advancing age; thus, HRQoL also decreased
ith age.36,37
The MELD index was also used in the present study since it
s the main criteria for allocation in liver transplantation wait-
ng list. Most individuals had low MELD indices (scores <15)
nd were therefore considered to be at low risk of mortality.
o correlation was observed between MELD and CLDQ scores.
ay et al. (2010) using CLDQ veriﬁed a weak correlation with
ELD and concluded that MELD scores poorly predicted QoL,
s evidenced in the present study.38 However, a positive corre-
ation was found for MELD scores and age, indicating that as
ge increases, MELD scores also increase, along with the risk
f mortality due to liver disease. Luca et al. (2007) have sug-
ested the inclusion of age into the original MELD formula in
rder to improve the predictive survival accuracy of patients
ith cirrhosis.39
Globally, CLD substantially contributes to mortality and
orbidity.5,6 Thus, understanding patients’ HRQoL and the
xtent of debilitation is extremely important. A limited
umber of studies have been conducted to evaluate
RQoL in patients with liver disease in Brazil, most of
hich used generic instruments; even so, HCV infection
as found to have a substantial impact on patients’
RQoL.13,40–42Health, as a social right of all citizens, requires direct and
positive state intervention by providing services for diagnosis,
treatment, and medical monitoring of diseases including CLD
to improve their HRQoL.
This study has some limitations: the cross sectional nature
of the study does not allow conclusions about causality; the
inclusion of outpatients from one single center; and the neces-
sity of a longitudinal study to determine the true impact on
HRQoL in a large population based study.
In conclusion, this study found high mean CLDQ scores
among a signiﬁcant number of CLD patients particularly
among those with low family income implying low HRQoL.
This suggests that early identiﬁcation of at-risk individuals
with low income could help develop and assess relevant
health programs intended to improve patients’ HRQoL. In
addition, MELD scores did not signiﬁcantly predict QoL.
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